baha the information company

baha is a leading provider of real-time market data, financial news, technology and solutions for the financial industry. baha offers real-time data terminals for professionals, global financial market data covering over 12 million financial instruments on more than 150 exchanges, as well as 24/7 breaking news with global coverage and free web and mobile apps. From a total of around 200 real-time data providers worldwide, only Reuters 1851, Bloomberg 1981 and now baha in 2021 were named after the founder.

UC BON.CAP.CERT. 03/25 SNW/ DE000HD4UWY1 /

9/18/2024 11:45:27 AM	Chg.+0.190	Bid9/18/2024	Ask9/18/2024	Underlying	Strike price	Expiration date	Option type
102.460EUR	+0.19%	102.450 Bid Size: 4,000	102.460 Ask Size: 4,000	SANOFI SA INHABER ...	- -	3/28/2025	Call

GlobeNewswire 9/2 Press Release: Tolebrutinib meets primary endpoint in HERCULES phase 3 study, the first and only to ...

GlobeNewswire 8/26 Latest Dupixent® (dupilumab) and Itepekimab Data at ERS Highlight Scientific Innovation and Leadersh...

GlobeNewswire 8/14 Anaptys Announces Pricing of $100 Million Underwritten Registered Direct Offering

GlobeNewswire 8/13 Vigil Neuroscience Reports Second Quarter 2024 Financial Results and Provides Business Update

GlobeNewswire 8/12 MeiraGTx Announces $50 Million Offering of Ordinary Shares led by Sanofi and Reports Second Quarter ...

GlobeNewswire 8/12 MeiraGTx Announces Pricing of Offering of Ordinary Shares Led by Sanofi

GlobeNewswire 8/8 Press Release: Sarclisa induction treatment demonstrated significantly improved progression-free sur...

GlobeNewswire 8/6 Alzheimer's Disease Diagnostics & Therapeutics Market Driven by Use of Biomarkers and Advancing R&D ...

GlobeNewswire 8/5 Fierce Biotech Names Recludix Pharma a “Fierce 15” Biotech Company of 2024

GlobeNewswire 8/2 Madrigal Pharmaceuticals Appoints Shannon Kelley as General Counsel

GlobeNewswire 8/1 Denali Therapeutics Reports Second Quarter 2024 Financial Results and Business Highlights

GlobeNewswire 8/1 Regeneron Reports Second Quarter 2024 Financial and Operating Results

GlobeNewswire 7/31 Fulcrum Therapeutics Announces Recent Business Highlights and Financial Results for Second Quarter 2...

GlobeNewswire 7/25 Press Release: Online availability of Sanofi’s half-year financial report for 2024

TeleTrader 7/25 Europe lower premarket as earnings pour in

TeleTrader 7/25 Sanofi net sales up 7.8% to €10.7B in Q2

GlobeNewswire 7/25 Press Release: Sanofi Q2 - strong performance with 10% sales growth; 2024 guidance upgraded

GlobeNewswire 7/24 US Hematologists Express High Unmet Need in Treatments for Warm Autoimmune Hemolytic Anemia and Cold...

GlobeNewswire 7/18 Takeda’s Eohilia Sees Strong Early Adoption and Growth Potential in Eosinophilic Esophagitis, Accord...

GlobeNewswire 7/17 Press Release: NEJM publishes ALTUVIIIO XTEND-Kids phase 3 data supporting its potential to transfor...

GlobeNewswire 7/12 FluGen’s Intranasal M2SR Flu Vaccine, Co-Administered with High Dose Vaccine, in Older Adults Shows ...

GlobeNewswire 7/11 Nurix Therapeutics Reports Second Quarter Fiscal 2024 Financial Results and Provides a Corporate Upd...

GlobeNewswire 7/8 Kymera Announces Expansion of KT-474 (SAR444656) HS and AD Phase 2 Studies Following Interim Review ...

GlobeNewswire 7/3 Dupixent® (dupilumab) Approved in the European Union as the First-ever Targeted Therapy for Patients...

GlobeNewswire 7/3 Press Release: Dupixent approved in the EU as the first-ever targeted therapy for patients with COPD

UC BON.CAP.CERT. 03/25 SNW/ DE000HD4UWY1 /

If you wish to receive reply to your feedback, please provide your email address.